Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (USD)150.50
  • Today's Change2.74 / 1.85%
  • Shares traded880.95k
  • 1 Year change+25.37%
  • Beta0.4687
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.

  • Revenue in USD (TTM)236.33bn
  • Net income in USD1.84bn
  • Incorporated2001
  • Employees38.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABC:NYQ since
FirstView LLCDeal completed19 Aug 202119 Aug 2021Deal completed26.92%--
Data delayed at least 15 minutes, as of Aug 12 2022 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Incyte Corporation3.32bn945.01m16.40bn2.09k17.444.0316.374.974.254.2514.9118.410.724.375.921,585,708.0020.495.8924.757.0595.3295.8828.467.983.857.770.00830.0011.9821.98420.8055.538.52--
Cardinal Health Inc176.85bn-955.00m16.83bn47.30k------0.0967-3.55-3.55621.06-2.554.1111.4318.643,738,837.00-2.22-0.5466-5.97-1.293.634.70-0.5395-0.1510.5369.651.14--6.245.98116.53-15.60-2.974.66
Biomarin Pharmaceutical Inc1.91bn50.15m17.75bn3.05k414.763.95114.449.310.23150.252810.2124.290.31750.61244.29627,819.100.8328-0.9720.9007-1.1275.7676.742.62-2.913.69-8.500.1935---0.762210.58-1,590.90---4.28--
ICON PLC7.59bn209.90m18.79bn39.30k96.622.4325.452.612.522.5292.3599.920.736--4.80197,976.302.077.222.509.5327.7330.262.819.57--3.010.3825--95.9326.88-53.91-10.1917.09--
Catalent Inc4.70bn486.90m19.38bn17.30k40.624.3624.134.302.782.7826.8225.880.49274.974.14271,861.305.384.206.074.7833.8332.1410.928.332.235.280.47470.0029.2116.69205.7836.5337.50--
Gartner Inc5.10bn735.66m23.23bn16.60k33.90--25.394.668.868.8661.35-1.800.7405--4.39307,341.3010.684.1219.137.0669.4265.0014.426.65--12.971.06--15.4814.13197.5032.603.71--
Alnylam Pharmaceuticals, Inc.884.25m-980.72m26.81bn1.67k--159.45--31.49-8.17-8.177.371.450.25861.697.19531,078.10-28.68-32.56-34.85-37.9483.40---110.91-223.643.62-2.990.7938--71.3178.070.6358--3.42--
DuPont de Nemours Inc15.14bn1.23bn29.37bn28.00k25.391.1911.472.012.393.6529.3850.960.33543.965.94540,642.902.87-0.22273.25-0.28934.6331.608.56-1.612.125.060.3016--16.15-19.13172.14-15.09-25.20-26.30
AmerisourceBergen Corp.236.33bn1.84bn29.99bn38.00k16.71134.9111.970.12778.718.711,117.751.084.1814.8012.096,219,
Seagen Inc1.78bn-739.80m32.39bn2.68k--11.04--18.22-4.04-4.049.7015.910.46891.504.35664,625.40-19.51-5.22-22.62-6.0079.5887.67-41.61-9.784.04-211.850.00---27.6330.36-209.91--13.46--
Iqvia Holdings Inc14.14bn1.16bn43.38bn82.00k40.038.3619.553.165.995.9972.9828.680.5847--5.71178,936.704.811.776.062.1434.4234.308.233.64--4.950.70460.0022.1415.28246.2468.0831.30--
Data as of Aug 12 2022. Currency figures normalised to Amerisourcebergen Corp's reporting currency: US Dollar USD

Institutional shareholders

29.42%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202218.30m8.74%
BlackRock Fund Advisorsas of 30 Jun 20228.26m3.95%
SSgA Funds Management, Inc.as of 31 Mar 20226.93m3.31%
JPMorgan Investment Management, Inc.as of 30 Jun 20226.60m3.15%
Fidelity Management & Research Co. LLCas of 30 Jun 20225.40m2.58%
Boston Partners Global Investors, Inc.as of 30 Jun 20224.53m2.16%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20223.42m1.64%
Geode Capital Management LLCas of 30 Jun 20222.94m1.40%
BlackRock Investment Management (UK) Ltd.as of 30 Jun 20222.70m1.29%
BlackRock Advisors LLCas of 30 Jun 20222.54m1.21%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.